MAPT and neurodegenerative disease: By analysing related neurodegenerative diseases for SHIP2 labelling, we provided clear evidence that amyloid pathology is the key driving factor that leads to the increase in SHIP2 immunoreactivity, but not other neuropathological aggregates such as alpha-synuclein, TDP-43 or tau.